Patient demographics
| Variable . | All patients (N = 119) . | Elra-treated patients (n = 40) . | Tec-treated patients (n = 45) . | Linvo-treated patients (n = 10) . | Tal-treated patients (n = 23) . | Tec/Tal-treated patients (n = 1) . |
|---|---|---|---|---|---|---|
| Treatment, n (%) | ||||||
| Elra | 40 (33.6) | 45 (100) | ||||
| Tec | 45 (37.8) | 40 (100) | 10 (100) | |||
| Linvo | 10 (8.4) | |||||
| Tal | 23 (19.3) | 23 (100) | ||||
| Tec/Tal | 1 (0.8) | 1 (100) | ||||
| Age, y | ||||||
| Median (range) | 67 (35-87) | 70 (53-87) | 67 (35-84) | 53 (40-71) | 65 (40-80) | 52 |
| ≥75, n (%) | 29 (24.4) | 12 (30) | 12 (26.7) | 0 (0) | 5 (21.7) | 0 (0) |
| Sex, n (%) | ||||||
| Female | 62 (52.1) | 23 (57.5) | 28 (62.2) | 1 (10) | 10 (43.5) | 0 (0) |
| Male | 57 (47.9) | 17 (42.50) | 17 (37.8) | 9 (90) | 13 (56.5) | 1 (100) |
| Race | ||||||
| Black | 22 (18.5) | 6 (15) | 10 (22.2) | 0 (0) | 6 (26.1) | 0 (0) |
| White | 97 (81.5) | 34 (85) | 35 (77.8) | 10 (100) | 17 (73.9) | 1 (100) |
| Hispanic ethnicity, n (%) | 49 (41.2) | 20 (50) | 16 (35.6) | 6 (60) | 7 (30.4) | 0 (0) |
| ECOG PS, n (%) | ||||||
| 0-1 | 84 (70.6) | 28 (70) | 29 (64.4) | 10 (100) | 16 (70) | 1 (100) |
| 2 | 28 (23.5) | 9 (22.5) | 12 (26.7) | 0 (0) | 7 (30.4) | 0 (0) |
| 3-4 | 7 (5.9) | 3 (7.5) | 4 (8.9) | 0 (0) | 0 (0) | 0 (0) |
| Met ≥1 exclusion criteria,∗ n (%) | 76 (63.9) | 28 (70) | 31 (68.9) | 1 (10) | 15 (65.2) | 1 (100) |
| High-risk FISH/cytogenetics,† n (%) | 32 (26.9) | 12 (30) | 11 (24.4) | 3 (30) | 6 (26.1) | 0 (0) |
| Previous lines of therapy, median (range) | 4.5 (1-16) | 4 (2-15) | 5 (1-12) | 2 (1-2) | 6 (3-16) | 5 (5) |
| Previous drug exposure, n (%) | ||||||
| Any BCMA therapy | 28 (23.5) | 5 (12.5) | 4 (8.9) | 0 (0) | 18 (78.3) | 1 (100) |
| Stem cell transplant | 47 (39.5) | 18 (45) | 14 (31.1) | 0 (0) | 15 (65.2) | 0 (0) |
| CAR T-cell therapy | 12 (10.1) | 0 (0) | 1 (2.2) | 0 (0) | 10 (43.5) | 1 (100) |
| Triple-class | 106 (89.1) | 40 (100) | 37 (82.2) | 5 (50) | 23 (100) | 1 (100) |
| Penta-drug | 64 (53.8) | 21 (52.5) | 22 (48.9) | 0 (0) | 20 (87) | 1 (100) |
| Refractory, n (%) | ||||||
| Triple-class | 89 (74.8) | 37 (92.5) | 29 (64.4) | 0 (0) | 22 (95.7) | 1 (100) |
| Penta-drug | 28 (23.5) | 9 (22.5) | 6 (13.3) | 0 (0) | 12 (52.2) | 1 (100) |
| Variable . | All patients (N = 119) . | Elra-treated patients (n = 40) . | Tec-treated patients (n = 45) . | Linvo-treated patients (n = 10) . | Tal-treated patients (n = 23) . | Tec/Tal-treated patients (n = 1) . |
|---|---|---|---|---|---|---|
| Treatment, n (%) | ||||||
| Elra | 40 (33.6) | 45 (100) | ||||
| Tec | 45 (37.8) | 40 (100) | 10 (100) | |||
| Linvo | 10 (8.4) | |||||
| Tal | 23 (19.3) | 23 (100) | ||||
| Tec/Tal | 1 (0.8) | 1 (100) | ||||
| Age, y | ||||||
| Median (range) | 67 (35-87) | 70 (53-87) | 67 (35-84) | 53 (40-71) | 65 (40-80) | 52 |
| ≥75, n (%) | 29 (24.4) | 12 (30) | 12 (26.7) | 0 (0) | 5 (21.7) | 0 (0) |
| Sex, n (%) | ||||||
| Female | 62 (52.1) | 23 (57.5) | 28 (62.2) | 1 (10) | 10 (43.5) | 0 (0) |
| Male | 57 (47.9) | 17 (42.50) | 17 (37.8) | 9 (90) | 13 (56.5) | 1 (100) |
| Race | ||||||
| Black | 22 (18.5) | 6 (15) | 10 (22.2) | 0 (0) | 6 (26.1) | 0 (0) |
| White | 97 (81.5) | 34 (85) | 35 (77.8) | 10 (100) | 17 (73.9) | 1 (100) |
| Hispanic ethnicity, n (%) | 49 (41.2) | 20 (50) | 16 (35.6) | 6 (60) | 7 (30.4) | 0 (0) |
| ECOG PS, n (%) | ||||||
| 0-1 | 84 (70.6) | 28 (70) | 29 (64.4) | 10 (100) | 16 (70) | 1 (100) |
| 2 | 28 (23.5) | 9 (22.5) | 12 (26.7) | 0 (0) | 7 (30.4) | 0 (0) |
| 3-4 | 7 (5.9) | 3 (7.5) | 4 (8.9) | 0 (0) | 0 (0) | 0 (0) |
| Met ≥1 exclusion criteria,∗ n (%) | 76 (63.9) | 28 (70) | 31 (68.9) | 1 (10) | 15 (65.2) | 1 (100) |
| High-risk FISH/cytogenetics,† n (%) | 32 (26.9) | 12 (30) | 11 (24.4) | 3 (30) | 6 (26.1) | 0 (0) |
| Previous lines of therapy, median (range) | 4.5 (1-16) | 4 (2-15) | 5 (1-12) | 2 (1-2) | 6 (3-16) | 5 (5) |
| Previous drug exposure, n (%) | ||||||
| Any BCMA therapy | 28 (23.5) | 5 (12.5) | 4 (8.9) | 0 (0) | 18 (78.3) | 1 (100) |
| Stem cell transplant | 47 (39.5) | 18 (45) | 14 (31.1) | 0 (0) | 15 (65.2) | 0 (0) |
| CAR T-cell therapy | 12 (10.1) | 0 (0) | 1 (2.2) | 0 (0) | 10 (43.5) | 1 (100) |
| Triple-class | 106 (89.1) | 40 (100) | 37 (82.2) | 5 (50) | 23 (100) | 1 (100) |
| Penta-drug | 64 (53.8) | 21 (52.5) | 22 (48.9) | 0 (0) | 20 (87) | 1 (100) |
| Refractory, n (%) | ||||||
| Triple-class | 89 (74.8) | 37 (92.5) | 29 (64.4) | 0 (0) | 22 (95.7) | 1 (100) |
| Penta-drug | 28 (23.5) | 9 (22.5) | 6 (13.3) | 0 (0) | 12 (52.2) | 1 (100) |
ECOG PS, Eastern Cooperative Oncology Group performance status; Elra, elranatamab; FISH, fluorescence in situ hybridization; Linvo, linvoseltamab; Tal, talquetamab; Tec, teclistamab.
Exclusion criteria based on registrational study for the given bispecific monoclonal antibody.
Presence of del17p, t(4;14), and/or t(14;16) as assessed at diagnosis or before initiation of bispecific antibody therapy.